Skip to main content
SpringerLink
Log in

Hepatocellular Carcinoma: Surgical Management and Evolving Therapies

  • Chapter
  • First Online:
Gastrointestinal Malignancies

Part of the book series: Cancer Treatment and Research ((CTAR))

Abstract

HCC is the second leading cause of cancer death worldwide. The majority of cases arise within the background of liver cirrhosis and are most commonly related to chronic hepatitis B and C viral infection. Surgical resection, liver transplantation, and tumour ablation are potentially curative modalities in cases of localized, non-metastatic, hepatocellular carcinoma. Systemic sorafenib has been shown to be marginally effective in slow disease progression in patients whose cirrhosis is so severe that they are not candidates for liver directed therapy and in those with metastatic disease. Several large prospective and retrospective studies have demonstrated transplantation to provide better long term outcomes than resection in patients with small volume carcinoma. Other small retrospective series have demonstrated similar outcomes for patients with well matched tumour characteristics and compensated cirrhosis. There is not even level one evidence to guide the choice of modality to be used in individual cases and treatment algorithms vary widely among high volume centres. Newer and emerging techniques and approaches such as laparoscopic liver resection and living donor transplantation continue to evolve and impact choice of treatment in absence of well-controlled comparative trials. For locally advanced disease and in patients with significant cirrhosis, interventional technologies such as transarterial chemoembolization or transarterial radioembolization can provide disease control or result in tumour regression and hypertrophy in the future liver remnant and may allow interval resection or down-staging to liver transplantation. Improving transarterial, surgical, and transplant techniques continue to expand the surgical and interventional options for managing localized HCC and are driving a shift towards aggressive multimodality therapy in patients with localized hepatoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108

    Article  PubMed  Google Scholar 

  2. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750

    Article  CAS  PubMed  Google Scholar 

  3. Suriawinata AA, Thung SN (2002) Malignant liver tumors. Clin Liver Dis 6:527–54 (ix)

    Google Scholar 

  4. Proneth A, Zeman F, Schlitt HJ, Schnitzbauer AA (2014) Is resection or transplantation the ideal treatment in patients with hepatocellular carcinoma in cirrhosis if both are possible? A systematic review and metaanalysis. Ann Surg Oncol 21:3096–3107

    Article  PubMed  Google Scholar 

  5. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C (2010) A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 51:1274–1283

    Article  PubMed  Google Scholar 

  6. Barbara L, Benzi G, Gaiani S et al (1992) Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 16:132–137

    Article  CAS  PubMed  Google Scholar 

  7. Nagasue N, Yukaya H, Hamada T, Hirose S, Kanashima R, Inokuchi K (1984) The natural history of hepatocellular carcinoma. A study of 100 untreated cases. Cancer 54:1461–1465

    Article  CAS  PubMed  Google Scholar 

  8. SEER Stat Fact Sheets: Liver and Intrahepatic Bile Duct Cancer. National Cancer Institute (2015). http://seer.cancer.gov/statfacts/html/livibd.html

  9. Beasley RP, Hwang LY, Lin CC, Chien CS (1981) Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 2:1129–1133

    Article  CAS  PubMed  Google Scholar 

  10. Kew MC (2010) Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris) 58:273–277

    Article  CAS  Google Scholar 

  11. Tsukuma H, Hiyama T, Tanaka S et al (1993) Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328:1797–1801

    Article  CAS  PubMed  Google Scholar 

  12. Chen CF, Lee WC, Yang HI et al (2011) Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 141:1240–1248 (8 e1-2)

    Google Scholar 

  13. Tseng TC, Liu CJ, Yang HC et al (2012) High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 142:1140–1149 (e3; quiz e13-4)

    Google Scholar 

  14. Chen JD, Yang HI, Iloeje UH et al (2010) Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 138:1747–1754

    Article  PubMed  Google Scholar 

  15. Omland LH, Jepsen P, Krarup H et al (2012) Liver cancer and non-Hodgkin lymphoma in hepatitis C virus-infected patients: results from the DANVIR cohort study. Int J Cancer 130:2310–2317

    Article  CAS  PubMed  Google Scholar 

  16. Huang YT, Jen CL, Yang HI et al (2011) Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol 29:3643–3650

    Article  PubMed  PubMed Central  Google Scholar 

  17. Yang JD, Kim WR, Coelho R et al (2011) Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol 9:64–70

    Article  PubMed  Google Scholar 

  18. Chen CJ, Liang KY, Chang AS et al (1991) Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology 13:398–406

    Article  CAS  PubMed  Google Scholar 

  19. Trichopoulos D, Bamia C, Lagiou P et al (2011) Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J Natl Cancer Inst 103:1686–1695

    Article  PubMed  PubMed Central  Google Scholar 

  20. Tanaka K, Hirohata T, Takeshita S et al (1992) Hepatitis B virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: a case-control study in Fukuoka, Japan. Int J Cancer 51:509–514

    Article  CAS  PubMed  Google Scholar 

  21. Satapathy SK, Sanyal AJ (2015) Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis 35:221–235

    Article  PubMed  Google Scholar 

  22. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN (2010) The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51:1972–1978

    Article  PubMed  Google Scholar 

  23. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G (1985) Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 313:1256–1262

    Article  CAS  PubMed  Google Scholar 

  24. Liang Y, Yang Z, Zhong R (2012) Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis. Hepatology 56:1409–1417

    Article  PubMed  Google Scholar 

  25. Nelson DR, Teckman J, Di Bisceglie AM, Brenner DA (2012) Diagnosis and management of patients with alpha1-antitrypsin (A1AT) deficiency. Clin Gastroenterol Hepatol 10:575–580

    Article  PubMed  Google Scholar 

  26. Qian GS, Ross RK, Yu MC et al (1994) A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People’s Republic of China. Cancer Epidemiol Biomark Prev 3:3–10

    CAS  Google Scholar 

  27. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC (2012) Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 107:46–52

    Article  CAS  PubMed  Google Scholar 

  28. Loomba R, Liu J, Yang HI et al (2013) Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. Clin Gastroenterol Hepatol 11(1636–45):e1–e3

    PubMed  Google Scholar 

  29. Bruix J, Sherman M (2011) American Association for the study of liver D. Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022

    Article  PubMed  PubMed Central  Google Scholar 

  30. Zhang BH, Yang BH, Tang ZY (2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130:417–422

    PubMed  Google Scholar 

  31. Song P, Tobe RG, Inagaki Y et al (2012) The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int 32:1053–1063

    Article  PubMed  Google Scholar 

  32. Benson AB 3rd, Abrams TA, Ben-Josef E et al (2009) NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 7:350–391

    CAS  PubMed  PubMed Central  Google Scholar 

  33. European Association For The Study Of The L, European Organisation For R, Treatment Of C (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943

    Google Scholar 

  34. Poon D, Anderson BO, Chen LT et al (2009) Management of hepatocellular carcinoma in Asia: consensus statement from the Asian oncology summit 2009. Lancet Oncol 10:1111–1118

    Article  PubMed  Google Scholar 

  35. Huitzil-Melendez FD, Capanu M, O’Reilly EM et al (2010) Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol 28:2889–2895

    Article  PubMed  PubMed Central  Google Scholar 

  36. Vauthey JN, Lauwers GY, Esnaola NF et al (2002) Simplified staging for hepatocellular carcinoma. J Clin Oncol 20:1527–1536

    Article  PubMed  Google Scholar 

  37. Okuda K, Ohtsuki T, Obata H et al (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918–928

    Article  CAS  PubMed  Google Scholar 

  38. The Cancer of the Liver Italian Program Investigators (CLIP) (2000) Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 31:840–845

    Google Scholar 

  39. Kudo M, Chung H, Osaki Y (2003) Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan integrated staging score (JIS score). J Gastroenterol 38:207–215

    Article  PubMed  Google Scholar 

  40. Vauthey JN, Dixon E, Abdalla EK et al (2010) Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) 12:289–299

    Article  Google Scholar 

  41. Fong ZV, Tanabe KK (2014) The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. Cancer 120:2824–2838

    Article  PubMed  Google Scholar 

  42. Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699

    Article  CAS  PubMed  Google Scholar 

  43. Child CGTJ (1964) The Liver and portal hypertension. WB Saunders, Philadelphia

    Google Scholar 

  44. Mansour A, Watson W, Shayani V, Pickleman J (1997) Abdominal operations in patients with cirrhosis: still a major surgical challenge. Surgery 122:730–735 (discussion 5-6)

    Google Scholar 

  45. Belghiti J, Regimbeau JM, Durand F et al (2002) Resection of hepatocellular carcinoma: a European experience on 328 cases. Hepatogastroenterology 49:41–46

    CAS  PubMed  Google Scholar 

  46. Kamath PS, Wiesner RH, Malinchoc M et al (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33:464–470

    Article  CAS  PubMed  Google Scholar 

  47. Ioannou GN, Perkins JD, Carithers RL Jr (2008) Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 134:1342–1351

    Article  PubMed  Google Scholar 

  48. Teh SH, Sheppard BC, Schwartz J, Orloff SL (2008) Model for end-stage liver disease score fails to predict perioperative outcome after hepatic resection for hepatocellular carcinoma in patients without cirrhosis. Am J Surg 195:697–701

    Article  PubMed  Google Scholar 

  49. Bruix J, Castells A, Bosch J et al (1996) Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 111:1018–1022

    Article  CAS  PubMed  Google Scholar 

  50. Boleslawski E, Petrovai G, Truant S et al (2012) Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis. Br J Surg 99:855–863

    Article  CAS  PubMed  Google Scholar 

  51. Pang Q, Qu K, Zhang JY et al (2015) The prognostic value of platelet count in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Medicine (Baltimore) 94:e1431

    Article  PubMed Central  Google Scholar 

  52. Kubota K, Makuuchi M, Kusaka K et al (1997) Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology 26:1176–1181

    CAS  PubMed  Google Scholar 

  53. Shoup M, Gonen M, D’Angelica M et al (2003) Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 7:325–330

    Article  PubMed  Google Scholar 

  54. Vauthey JN, Chaoui A, Do KA et al (2000) Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery 127:512–519

    Article  CAS  PubMed  Google Scholar 

  55. Farges O, Belghiti J, Kianmanesh R et al (2003) Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 237:208–217

    PubMed  PubMed Central  Google Scholar 

  56. Abulkhir A, Limongelli P, Healey AJ et al (2008) Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 247:49–57

    Article  PubMed  Google Scholar 

  57. Hemming AW, Reed AI, Howard RJ et al (2003) Preoperative portal vein embolization for extended hepatectomy. Ann Surg 237:686–691 (discussion 91-3)

    Google Scholar 

  58. Palavecino M, Chun YS, Madoff DC et al (2009) Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: perioperative outcome and survival. Surgery 145:399–405

    Article  PubMed  Google Scholar 

  59. Fidelman N, Kerlan RK Jr (2015) Transarterial chemoembolization and 90Y radioembolization for hepatocellular carcinoma: review of current applications beyond intermediate-stage disease. AJR Am J Roentgenol 205:742–752

    Article  PubMed  Google Scholar 

  60. Kokudo N, Bandai Y, Imanishi H et al (1996) Management of new hepatic nodules detected by intraoperative ultrasonography during hepatic resection for hepatocellular carcinoma. Surgery 119:634–640

    Article  CAS  PubMed  Google Scholar 

  61. Takigawa Y, Sugawara Y, Yamamoto J et al (2001) New lesions detected by intraoperative ultrasound during liver resection for hepatocellular carcinoma. Ultrasound Med Biol 27:151–156

    Article  CAS  PubMed  Google Scholar 

  62. Man K, Fan ST, Ng IO, Lo CM, Liu CL, Wong J (1997) Prospective evaluation of Pringle maneuver in hepatectomy for liver tumors by a randomized study. Ann Surg 226:704–711 (discussion 11-3)

    Google Scholar 

  63. Belghiti J, Noun R, Malafosse R et al (1999) Continuous versus intermittent portal triad clamping for liver resection: a controlled study. Ann Surg 229:369–375

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Abdalla EK, Noun R, Belghiti J (2004) Hepatic vascular occlusion: which technique? Surg Clin North Am 84:563–585

    Article  PubMed  Google Scholar 

  65. Regimbeau JM, Kianmanesh R, Farges O, Dondero F, Sauvanet A, Belghiti J (2002) Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocellular carcinoma. Surgery 131:311–317

    Article  PubMed  Google Scholar 

  66. Liu CL, Fan ST, Lo CM, Tung-Ping Poon R, Wong J (2000) Anterior approach for major right hepatic resection for large hepatocellular carcinoma. Ann Surg 232:25–31

    Google Scholar 

  67. Liu CL, Fan ST, Cheung ST, Lo CM, Ng IO, Wong J (2006) Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study. Ann Surg 244:194–203

    Article  PubMed  PubMed Central  Google Scholar 

  68. Agrawal S, Belghiti J (2011) Oncologic resection for malignant tumors of the liver. Ann Surg 253:656–665

    Article  PubMed  Google Scholar 

  69. Bilimoria MM, Lauwers GY, Doherty DA et al (2001) Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg 136:528–535

    Article  CAS  PubMed  Google Scholar 

  70. Hasegawa K, Kokudo N, Imamura H et al (2005) Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg 242:252–259

    Article  PubMed  PubMed Central  Google Scholar 

  71. Nguyen KT, Gamblin TC, Geller DA (2009) World review of laparoscopic liver resection—2,804 patients. Ann Surg 250:831–841

    Article  PubMed  Google Scholar 

  72. Siniscalchi A, Ercolani G, Tarozzi G et al (2014) Laparoscopic versus open liver resection: differences in intraoperative and early postoperative outcome among cirrhotic patients with hepatocellular carcinoma—a retrospective observational study. HPB Surg 2014:871251

    Article  PubMed  PubMed Central  Google Scholar 

  73. Tanaka S, Takemura S, Shinkawa H et al (2015) Outcomes of pure laparoscopic versus open hepatic resection for hepatocellular carcinoma in cirrhotic patients: a case-control study with propensity score matching. Eur Surg Res 55:291–301

    Article  PubMed  Google Scholar 

  74. Takahara T, Wakabayashi G, Beppu T et al (2015) Long-term and perioperative outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with propensity score matching: a multi-institutional Japanese study. J Hepatobiliary Pancreat Sci 22:721–727

    Article  PubMed  Google Scholar 

  75. Li W, Zhou X, Huang Z et al (2014) Laparoscopic surgery minimizes the release of circulating tumor cells compared to open surgery for hepatocellular carcinoma. Surg Endosc

    Google Scholar 

  76. Poon RT, Fan ST, Lo CM et al (2001) Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 234:63–70

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Nathan H, Segev DL, Mayo SC et al (2012) National trends in surgical procedures for hepatocellular carcinoma: 1998–2008. Cancer 118:1838–1844

    Article  PubMed  Google Scholar 

  78. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O (2000) Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 191:38–46

    Article  CAS  PubMed  Google Scholar 

  79. Adam R, Bhangui P, Vibert E et al (2012) Resection or transplantation for early hepatocellular carcinoma in a cirrhotic liver: does size define the best oncological strategy? Ann Surg 256:883–891

    Article  PubMed  Google Scholar 

  80. Cha CH, Ruo L, Fong Y et al (2003) Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg 238:315–321 (discussion 21-3)

    Google Scholar 

  81. Rayya F, Harms J, Bartels M, Uhlmann D, Hauss J, Fangmann J (2008) Results of resection and transplantation for hepatocellular carcinoma in cirrhosis and noncirrhosis. Transplant Proc 40:933–935

    Article  CAS  PubMed  Google Scholar 

  82. Koniaris LG, Levi DM, Pedroso FE et al (2011) Is surgical resection superior to transplantation in the treatment of hepatocellular carcinoma? Ann Surg 254:527–537 (discussion 37-8)

    Google Scholar 

  83. Zhou XD, Tang ZY, Yang BH et al (2001) Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 91:1479–1486

    Article  CAS  PubMed  Google Scholar 

  84. Jwo SC, Chiu JH, Chau GY, Loong CC, Lui WY (1992) Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection. Hepatology 16:1367–1371

    Article  CAS  PubMed  Google Scholar 

  85. Yamamoto J, Kosuge T, Takayama T et al (1996) Recurrence of hepatocellular carcinoma after surgery. Br J Surg 83:1219–1222

    Article  CAS  PubMed  Google Scholar 

  86. The Liver Cancer Study Group of Japan (1994) Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 74:2772–2780

    Google Scholar 

  87. Poon RT, Fan ST, Wong J (2002) Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. J Am Coll Surg 194:592–602

    Article  PubMed  Google Scholar 

  88. Pawlik TM, Poon RT, Abdalla EK et al (2005) Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 140:450–457 (discussion 7-8)

    Google Scholar 

  89. Yeh CN, Lee WC, Chen MF (2003) Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at Chang Gung memorial hospital. Ann Surg Oncol 10:1070–1076

    Article  PubMed  Google Scholar 

  90. Pesi B, Ferrero A, Grazi GL et al (2015) Liver resection with thrombectomy as a treatment of hepatocellular carcinoma with major vascular invasion: results from a retrospective multicentric study. Am J Surg 210:35–44

    Article  PubMed  Google Scholar 

  91. Faber W, Stockmann M, Kruschke JE, Denecke T, Bahra M, Seehofer D (2014) Implication of microscopic and macroscopic vascular invasion for liver resection in patients with hepatocellular carcinoma. Dig Surg 31:204–209

    Article  PubMed  Google Scholar 

  92. Nathan H, Hyder O, Mayo SC et al (2013) Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis. Ann Surg 258:1022–1027

    Article  PubMed  PubMed Central  Google Scholar 

  93. Decaens T, Roudot-Thoraval F, Hadni-Bresson S et al (2006) Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 12:1761–1769

    Article  PubMed  Google Scholar 

  94. Mazzaferro V (2007) Results of liver transplantation: with or without Milan criteria? Liver Transpl 13:S44–S47

    Article  PubMed  Google Scholar 

  95. Yao FY, Ferrell L, Bass NM et al (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33:1394–1403

    Article  CAS  PubMed  Google Scholar 

  96. Duffy JP, Vardanian A, Benjamin E et al (2007) Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 246:502–509 (discussion 9-11)

    Google Scholar 

  97. Lai Q, Nudo F, Mennini G et al (2013) Expanded criteria for hepatocellular carcinoma after liver transplantation: a 20-year evolution. Hepatogastroenterology 60:2039–2041

    CAS  PubMed  Google Scholar 

  98. Foltys D, Zimmermann T, Kaths M et al (2014) Hepatocellular carcinoma in Child’s A cirrhosis: a retrospective analysis of matched pairs following liver transplantation vs. liver resection according to the intention-to-treat principle. Clin Transplant 28:37–46

    Article  PubMed  Google Scholar 

  99. Piardi T, Gheza F, Ellero B et al (2012) Number and tumor size are not sufficient criteria to select patients for liver transplantation for hepatocellular carcinoma. Ann Surg Oncol 19:2020–2026

    Article  CAS  PubMed  Google Scholar 

  100. Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ (2003) The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 21:4329–4335

    Article  PubMed  Google Scholar 

  101. Rahman A, Assifi MM, Pedroso FE et al (2012) Is resection equivalent to transplantation for early cirrhotic patients with hepatocellular carcinoma? A meta-analysis. J Gastrointest Surg 16:1897–1909

    Article  PubMed  Google Scholar 

  102. Yamamoto J, Kosuge T, Saiura A et al (2007) Effectiveness of hepatic resection for early-stage hepatocellular carcinoma in cirrhotic patients: subgroup analysis according to Milan criteria. Jpn J Clin Oncol 37:287–295

    Article  PubMed  Google Scholar 

  103. Hanouneh IA, Macaron C, Lopez R, Aucejo F, Zein NN (2011) Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria. Transplant Proc 43:3813–3818

    Article  CAS  PubMed  Google Scholar 

  104. Choi HJ, Kim DG, Na GH, Han JH, Hong TH, You YK (2013) Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation. World J Gastroenterol 19:4737–4744

    Article  PubMed  PubMed Central  Google Scholar 

  105. Morioka D, Egawa H, Kasahara M et al (2007) Outcomes of adult-to-adult living donor liver transplantation: a single institution’s experience with 335 consecutive cases. Ann Surg 245:315–325

    Article  PubMed  PubMed Central  Google Scholar 

  106. Hu Z, Qian Z, Wu J et al (2015) Clinical outcomes and risk factors of hepatocellular carcinoma treated by liver transplantation: a multi-centre comparison of living donor and deceased donor transplantation. Clin Res Hepatol Gastroenterol

    Google Scholar 

  107. Xiao GQ, Song JL, Shen S, Yang JY, Yan LN (2014) Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation. World J Gastroenterol 20:10953–10959

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  108. Kaido T, Morita S, Tanaka S et al (2015) Long-term outcomes of hepatic resection versus living donor liver transplantation for hepatocellular carcinoma: a propensity score-matching study. Dis Markers 2015:425926

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  109. Figueras J, Jaurrieta E, Valls C et al (2000) Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. J Am Coll Surg 190:580–587

    Article  CAS  PubMed  Google Scholar 

  110. Vitale A, Huo TL, Cucchetti A et al (2015) Survival benefit of liver transplantation versus resection for hepatocellular carcinoma: impact of MELD score. Ann Surg Oncol 22:1901–1907

    Article  PubMed  Google Scholar 

  111. Lim KC, Wang VW, Siddiqui FJ et al (2015) Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria. Hepatology 61:227–237

    Article  PubMed  Google Scholar 

  112. Park HW, Hwang S, Ahn CS et al (2013) Long-term survival outcomes for living donor liver transplant recipients with pathologically nonviable hepatocellular carcinoma. Transplant Proc 45:3032–3034

    Article  PubMed  Google Scholar 

  113. Facciorusso A, Licinio R, Muscatiello N, Di Leo A, Barone M (2015) Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol 7:2009–2019

    Article  PubMed  PubMed Central  Google Scholar 

  114. Li H, Li B, Wei Y et al (2015) Preoperative transarterial chemoembolization does not increase hepatic artery complications after liver transplantation: a single center 12-year experience. Clin Res Hepatol Gastroenterol 39:451–457

    Article  PubMed  Google Scholar 

  115. Allard MA, Sebagh M, Ruiz A et al (2015) Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation? J Hepatol 63:83–92

    Article  PubMed  Google Scholar 

  116. Bharat A, Brown DB, Crippin JS et al (2006) Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. J Am Coll Surg 203:411–420

    Article  PubMed  Google Scholar 

  117. Lao OB, Weissman J, Perkins JD (2009) Pre-transplant therapy for hepatocellular carcinoma is associated with a lower recurrence after liver transplantation. Clin Transplant 23:874–881

    Article  PubMed  Google Scholar 

  118. Pompili M, Mirante VG, Rondinara G et al (2005) Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl 11:1117–1126

    Article  PubMed  Google Scholar 

  119. Mazzaferro V, Battiston C, Perrone S et al (2004) Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 240:900–909

    Article  PubMed  PubMed Central  Google Scholar 

  120. Vouche M, Habib A, Ward TJ et al (2014) Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology 60:192–201

    Article  PubMed  Google Scholar 

  121. Lewandowski RJ, Kulik LM, Riaz A et al (2009) A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 9:1920–1928

    Article  CAS  PubMed  Google Scholar 

  122. Adam R, Azoulay D, Castaing D et al (2003) Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg 238:508–518 (discussion 18-9)

    Google Scholar 

  123. Belghiti J, Cortes A, Abdalla EK et al (2003) Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 238:885–892 (discussion 92-3)

    Google Scholar 

  124. Poon RT, Fan ST, Lo CM, Liu CL, Wong J (2002) Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 235:373–382

    Article  PubMed  PubMed Central  Google Scholar 

  125. Poon RT, Fan ST (2004) Is primary resection and salvage transplantation for hepatocellular carcinoma a reasonable strategy? Ann Surg 240:925–928 (author reply 8)

    Google Scholar 

  126. Livraghi T, Meloni F, Di Stasi M et al (2008) Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 47:82–89

    Article  PubMed  Google Scholar 

  127. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC (2005) Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 54:1151–1156

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Chen MS, Li JQ, Zheng Y et al (2006) A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243:321–328

    Article  PubMed  PubMed Central  Google Scholar 

  129. Duan C, Liu M, Zhang Z, Ma K, Bie P (2013) Radiofrequency ablation versus hepatic resection for the treatment of early-stage hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis. World J Surg Oncol 11:190

    Article  PubMed  PubMed Central  Google Scholar 

  130. Huang J, Hernandez-Alejandro R, Croome KP et al (2011) Radiofrequency ablation versus surgical resection for hepatocellular carcinoma in Childs A cirrhotics-a retrospective study of 1,061 cases. J Gastrointest Surg 15:311–320

    Article  PubMed  Google Scholar 

  131. Weis S, Franke A, Mossner J, Jakobsen JC, Schoppmeyer K (2013) Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane Database Syst Rev 12:CD003046

    Google Scholar 

  132. Li GZ, Speicher PJ, Lidsky ME et al (2014) Hepatic resection for hepatocellular carcinoma: do contemporary morbidity and mortality rates demand a transition to ablation as first-line treatment? J Am Coll Surg 218:827–834

    Article  PubMed  Google Scholar 

  133. Zhou Y, Zhao Y, Li B et al (2010) Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol 10:78

    Article  PubMed  PubMed Central  Google Scholar 

  134. Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171

    Article  CAS  PubMed  Google Scholar 

  135. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442

    Article  CAS  PubMed  Google Scholar 

  136. Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL (2002) A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 94:1747–1752

    Article  PubMed  Google Scholar 

  137. Takayasu K, Arii S, Ikai I et al (2006) Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131:461–469

    Article  CAS  PubMed  Google Scholar 

  138. Salem R, Lewandowski RJ, Mulcahy MF et al (2010) Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138:52–64

    Article  CAS  PubMed  Google Scholar 

  139. Zhang Y, Li Y, Ji H, Zhao X, Lu H (2015) Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: a meta-analysis. Biosci Trends 9:289–298

    Article  PubMed  Google Scholar 

  140. Mosconi C, Cappelli A, Pettinato C, Golfieri R (2015) Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: role and perspectives. World J Hepatol 7:738–752

    Article  PubMed  PubMed Central  Google Scholar 

  141. Lau WY, Sangro B, Chen PJ et al (2013) Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology 84:311–318

    Article  CAS  PubMed  Google Scholar 

  142. Edeline J, Gilabert M, Garin E, Boucher E, Raoul JL (2015) Yttrium-90 microsphere radioembolization for hepatocellular carcinoma. Liver Cancer 4:16–25

    Article  CAS  PubMed  Google Scholar 

  143. Palmer DH (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:2498 (author reply-9)

    Google Scholar 

  144. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34

    Article  CAS  PubMed  Google Scholar 

  145. Clavien PA (2007) Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection? Ann Surg 245:843–845

    Article  PubMed  PubMed Central  Google Scholar 

  146. Lo CM, Liu CL, Chan SC et al (2007) A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 245:831–842

    Article  PubMed  PubMed Central  Google Scholar 

  147. Muto Y, Moriwaki H, Ninomiya M et al (1996) Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 334:1561–1567

    Article  CAS  PubMed  Google Scholar 

  148. Liu CJ, Chang J, Lee PH et al (2014) Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. World J Gastroenterol 20:11384–11393

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Vauthey JN, Ribero D, Abdalla EK et al (2007) Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment. J Am Coll Surg 204:1016–1027 (discussion 27-8)

    Google Scholar 

  150. Cillo U, Vitale A, Grigoletto F et al (2006) Prospective validation of the Barcelona clinic liver cancer staging system. J Hepatol 44:723–731

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University of Chicago Medicine, Chicago, IL, USA

    Olga Kantor

  2. Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA

    Marshall S. Baker

  3. Pritzker School of Medicine, Univeristy of Chicago, Chicago, IL, USA

    Marshall S. Baker

Authors
  1. Olga Kantor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marshall S. Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marshall S. Baker .

Editor information

Editors and Affiliations

  1. Department of Surgery, Northwestern University, Chicago, Illinois, USA

    David Bentrem

  2. Robert H. Lurie Cancer Center, Northwestern University, Chicago, Illinois, USA

    Al B. Benson

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Kantor, O., S. Baker, M. (2016). Hepatocellular Carcinoma: Surgical Management and Evolving Therapies. In: Bentrem, D., Benson, A. (eds) Gastrointestinal Malignancies. Cancer Treatment and Research. Springer, Cham. https://doi.org/10.1007/978-3-319-34244-3_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-34244-3_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-34242-9

  • Online ISBN: 978-3-319-34244-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation